Literature DB >> 15107713

[Neurodevelopmental hypothesis in schizophrenia].

D Gourion1, R Gourevitch, J-B Leprovost, J-P Olié H lôo, M-O Krebs.   

Abstract

The hypothesis for a neurodevelopmental basis to the underlying physiopathological disorder leading to schizophrenia has been proposed by many investigators for more than two decades. This hypothesis is supported by -several lines of evidence. Pregnancy and delivery complications, particularly those with known or presumed impact on fetal neurologic development, result in increased risk for psychotic disorders. Other possible etiologic candidates include viral infections. Minor physical anomalies, manifesting as slight anatomical defects of the head, hair, eyes, mouth, hands and feet, as dematoglyphic fluctuating asymmetries, are due to some injury occurring during the first or second trimester of fetal life, and are more common among patients with schizophrenia and in their unaffected siblings than in the general population. But a major Issue in a such neurodevelopmental model theory is the delayed onset of the schizophrenic disorder. Although early signs and prodromal symptoms can be defined retrospectively in patients who have developed schizophrenia, they do have to be confirmed as early predictors in prospective and longitudinal studies. Abnormalities in brain development and maturation seem to begin prenatally, but may continue throughout childhood and the observed changes during these periods must have -consequences for the neuronal circuitry and connectivity. Advances in brain imaging have now led to the identification of a great number of brain abnormalities in schizophrenia. The most consistently replicated structural anomaly present in the brains of patients with chronic schizophrenia is ventricular enlargement. These findings also include medial temporal lobe structures (which include the amygdala, hippocampus, and parahippocampal gyrus), and neocortical temporal lobe regions (superior temporal gyrus). There is also some evidence for frontal lobe abnormalities, particularly prefrontal gray matter and orbitofrontal regions. Similarly, there are findings for parietal lobe abnormalities (particularly of the inferior parietal lobule which includes both supramarginal and angular gyri) and subcortical abnormalities (basal ganglia, corpus callosum, and thalamus) but more equivocal evidence for cerebellar abnormalities. However, it is possible that the brain structural abnormalities observed in schizophrenia are not only due to neurodevelopmental anomalies, but also to an alteration in cortical plasticity and maturation processes that occurs over the long course of the disease. The genetic predisposition for schizophrenia has been confirmed in many studies. It is utterly disappointing that molecular genetic approaches have so far not yielded conclusive evidence for vulnerability or protection genes in schizophrenia. Future studies will likely benefit from: 1) studying more homogeneous patient groups, 2) studying high risk populations such as biological relatives of patients with schizophrenia, 3) using longitudinal and prospective methodological design in order to confirm the predictive validity of neurodevelopmental clues found in patients with schizophrenia, 4) applying newer strategies such as composite phenotypes of developmental origin, in combination with new genetic methods.

Entities:  

Mesh:

Year:  2004        PMID: 15107713     DOI: 10.1016/s0013-7006(04)95421-8

Source DB:  PubMed          Journal:  Encephale        ISSN: 0013-7006            Impact factor:   1.291


  7 in total

1.  Pbx Regulates Patterning of the Cerebral Cortex in Progenitors and Postmitotic Neurons.

Authors:  Olga Golonzhka; Alex Nord; Paul L F Tang; Susan Lindtner; Athena R Ypsilanti; Elisabetta Ferretti; Axel Visel; Licia Selleri; John L R Rubenstein
Journal:  Neuron       Date:  2015-12-06       Impact factor: 17.173

Review 2.  Beneficial effects of omega-3 fatty acid supplementation in schizophrenia: possible mechanisms.

Authors:  Mei-Chi Hsu; Yung-Sheng Huang; Wen-Chen Ouyang
Journal:  Lipids Health Dis       Date:  2020-07-03       Impact factor: 3.876

3.  Premorbid adjustment amongst outpatients with schizophrenia in a Nigerian psychiatric facility.

Authors:  Omokehinde O Fakorede; Adegboyega Ogunwale; Akinwande O Akinhanmi
Journal:  S Afr J Psychiatr       Date:  2021-05-28       Impact factor: 1.550

4.  Very early onset and greater vulnerability in schizophrenia: A clinical and neuroimaging study.

Authors:  Francesco Margari; Anna Presicci; Maria Giuseppina Petruzzelli; Patrizia Ventura; Franca Di Cuonzo; Michele Palma; Lucia Margari
Journal:  Neuropsychiatr Dis Treat       Date:  2008-08       Impact factor: 2.570

Review 5.  Cognitive Deficits in Schizophrenia: Understanding the Biological Correlates and Remediation Strategies.

Authors:  Adarsh Tripathi; Sujita Kumar Kar; Rashmi Shukla
Journal:  Clin Psychopharmacol Neurosci       Date:  2018-02-28       Impact factor: 2.582

6.  Early and very early-onset schizophrenia compared with adult-onset schizophrenia: French FACE-SZ database.

Authors:  Nathalie Coulon; Ophélia Godin; Ewa Bulzacka; Caroline Dubertret; Jasmina Mallet; Guillaume Fond; Lore Brunel; Méja Andrianarisoa; George Anderson; Isabelle Chereau; Hélène Denizot; Romain Rey; Jean-Michel Dorey; Christophe Lançon; Catherine Faget; Paul Roux; Christine Passerieux; Julien Dubreucq; Sylvain Leignier; Delphine Capdevielle; Myrtille André; Bruno Aouizerate; David Misdrahi; Fabrice Berna; Pierre Vidailhet; Marion Leboyer; Franck Schürhoff
Journal:  Brain Behav       Date:  2020-01-07       Impact factor: 2.708

7.  Plasma β-III tubulin, neurofilament light chain and glial fibrillary acidic protein are associated with neurodegeneration and progression in schizophrenia.

Authors:  Daniela Rodrigues-Amorim; Tania Rivera-Baltanás; María Del Carmen Vallejo-Curto; Cynthia Rodriguez-Jamardo; Elena de Las Heras; Carolina Barreiro-Villar; María Blanco-Formoso; Patricia Fernández-Palleiro; María Álvarez-Ariza; Marta López; Alejandro García-Caballero; José Manuel Olivares; Carlos Spuch
Journal:  Sci Rep       Date:  2020-08-31       Impact factor: 4.379

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.